Bionano Genomics, Inc. (BNGO) Stock Forecast
Data as of Sep 20, 2026Healthcare · Current price $1.74 (0.00%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
BNGO vs Sector & Market
| Metric | BNGO | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.26 | 2.42 |
| Analyst Count | 1 | 8 | 18 |
| Target Upside | +2580.1% | +22240.6% | +21.5% |
| P/E Ratio | -0.25 | 3.76 | 38.34 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $35M | $35M | $35M | 1 |
| 2027-12-31 | $47M | $47M | $47M | 1 |
| 2028-12-31 | $59M | $59M | $59M | 1 |
| 2029-12-31 | $72M | $72M | $72M | 1 |
| 2030-12-31 | $88M | $88M | $88M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-2.56 | $-2.56 | $-2.56 | 1 |
| 2027-12-31 | $-1.02 | $-1.02 | $-1.02 | 1 |
| 2028-12-31 | $-0.49 | $-0.49 | $-0.49 | 1 |
| 2029-12-31 | $-0.15 | $-0.15 | $-0.15 | 1 |
| 2030-12-31 | $0.36 | $0.36 | $0.36 | 1 |
Frequently Asked Questions
What is the analyst consensus for BNGO?
The consensus among 1 analysts covering Bionano Genomics, Inc. (BNGO) is Buy with an average price target of $46.50.
What is the highest price target for BNGO?
The highest analyst price target for BNGO is $175.00.
What is the lowest price target for BNGO?
The lowest analyst price target for BNGO is $1.00.
How many analysts cover BNGO?
1 analysts have issued ratings for Bionano Genomics, Inc. in the past 12 months.
Is BNGO a buy or sell right now?
Based on 1 analyst ratings, BNGO has a consensus rating of Buy (2.00/5) with a +2580.1% upside to the consensus target of $46.50.
What are the earnings estimates for BNGO?
Analysts estimate BNGO will report EPS of $-2.56 for the period ending 2026-12-31, with revenue estimated at $35M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.